Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies.
作者： Gino A. Vena , Nicoletta Cassano , Stefano Piaserico , Andrea Conti , Giampiero Girolomoni
DOI: 10.3109/08923973.2012.692381
关键词:
摘要: Etanercept is a dimeric fusion protein consisting of the extracellular portion tumor necrosis factor (TNF) p75 receptor and human IgG1 Fc fragment, which, similarly to physiological soluble TNF receptor, capable binding TNF-α lymphotoxin. The mechanism action etanercept in psoriatic disease other approved indications mediated by neutralization leading modulation immune response. Clinical trials have provided robust evidence supporting sustained efficacy safety psoriasis, as both intermittent continuous therapy. aim this manuscript was review profile psoriasis according clinical experience gained Italian dermatological centers derived from available publications on topic. Everyday practice confirms that valuable flexible therapeutic tool for management high-need patients.
core.ac.uk
informahealthcare.com参考文章(26)
Annamaria Mazzotta, Maria Esposito, Antonio Costanzo, Sergio Chimenti, Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments American Journal of Clinical Dermatology. ,vol. 10, pp. 319- 324 ,(2009) , 10.2165/11310770-000000000-00000
M. Esposito, A. Mazzotta, R. Saraceno, C. Schipani, S. Chimenti, Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. International Journal of Immunopathology and Pharmacology. ,vol. 22, pp. 219- 225 ,(2009) , 10.1177/039463200902200124
Clara De Simone, Magda D’Agostino, Rodolfo Capizzi, Angela Capponi, Antonio Venier, Giacomo Caldarola, Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis European Journal of Dermatology. ,vol. 21, pp. 568- 572 ,(2011) , 10.1684/EJD.2011.1330
N. Cassano, F. Loconsole, A. Miracapillo, M. Travaglini, M.D. Digiuseppe, M. Congedo, A. Galluccio, R. Buquicchio, V. Mastrandrea, M. Filieri, G. Raho, M. Pezza, G.A. Vena, Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group. International Journal of Immunopathology and Pharmacology. ,vol. 23, pp. 797- 802 ,(2010) , 10.1177/039463201002300314
Safety and efficacy study on etanercept in patients with plaque psoriasis. British Journal of Dermatology. ,vol. 152, pp. 187- 189 ,(2005) , 10.1111/J.1365-2133.2005.06306.X
E Daudén, CEM Griffiths, J-P Ortonne, K Kragballe, CT Molta, D Robertson, R Pedersen, J Estojak, R Boggs, Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The CRYSTEL study Journal of The European Academy of Dermatology and Venereology. ,vol. 23, pp. 1374- 1382 ,(2009) , 10.1111/J.1468-3083.2009.03321.X
J‐P Ortonne, A Taieb, AD Ormerod, D Robertson, J Foehl, R Pedersen, C Molta, B Freundlich, Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. British Journal of Dermatology. ,vol. 161, pp. 1190- 1195 ,(2009) , 10.1111/J.1365-2133.2009.09238.X
M. Esposito, A. Mazzotta, C. Casciello, S. Chimenti, Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology. ,vol. 216, pp. 355- 360 ,(2008) , 10.1159/000117706
Frank Bachmann, Georgios Kokolakis, Wolfram Sterry, Sandra Philipp, Etanercept: overview of clinical experience in the treatment of psoriasis and psoriatic arthritis International Journal of Clinical Rheumatology. ,vol. 6, pp. 135- 155 ,(2011) , 10.2217/IJR.10.104
R.J.B. Driessen, J.B. Boezeman, P.C.M. van de Kerkhof, E.M.G.J. de Jong, Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. British Journal of Dermatology. ,vol. 160, pp. 670- 675 ,(2009) , 10.1111/J.1365-2133.2008.09019.X